{Reference Type}: Journal Article
{Title}: Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus.
{Author}: Chen R;Li H;Zhu W;Cheng H;Li Y;Li X;Li F;Liu X;Hu S;Yan B;Zheng Y;Zuo Y;Dong G;Li X;
{Journal}: Expert Opin Drug Saf
{Volume}: 23
{Issue}: 6
{Year}: 2024 Jun 12
{Factor}: 4.011
{DOI}: 10.1080/14740338.2023.2233411
{Abstract}: <B>UNASSIGNED: </B>There are no local or international guidelines or consensus on the use of mAbs against the rabies virus.<BR><B>UNASSIGNED: </B>An expert group in the field of rabies prevention and control formulated the consensus presented in this paper.<BR><B>UNASSIGNED: </B>Class III exposed persons to rabies for the first time; Identify type II exposed persons with immune deficiency; those who are first exposed to Class II and re-exposed to Class III within 7 days. They can use ormutivimab injection after completing the PEP wound treatment. In the case of injection restrictions or a wound that is difficult to detect, it is recommended that the entire Ormutivimab dose be infiltrated close to the wound. For severe multi-wound bites, the recommended dosage of ormutivimab is 20 IU/kg. If the recommended dose cannot meet all of the wound infiltration requirements, appropriate dilution can be conducted at a dilution ratio of 3 ~ 5 times. If the requirements for infiltration cannot be met after dilution, it is recommended that the dosage be increased with caution (maximum dosage, 40 IU/kg). The use of Ormutivimab is safe and effective without any contraindications by all age groups.<BR><B>UNASSIGNED: </B>This consensus standardizes clinical use of Ormutivimab, improves post-exposure prophylaxis of rabies in China, reduces infection rate.